Fu-Shun Yen1, Jung-Nien Lai2,3, James Cheng-Chung Wei4,5,6, Lu-Ting Chiu7,8, Chih-Cheng Hsu9,10,11, Ming-Chih Hou12,13, Chii-Min Hwu14,15. 1. Dr. Yen's Clinic, No. 15, Shanying Road, Gueishan District, Taoyuan, 33354, Taiwan. 2. School of Chinese Medicine, College of Chinese Medicine, China Medical University, No. 91, Hsueh-Shih Road, Taichung, 40402, Taiwan. 3. Department of Chinese Medicine, China Medical University Hospital, 3F., No. 373-2, Jianxing Road, Taichung, 40459, Taiwan. 4. Department of Allergy, Immunology and Rheumatology, Chung Shan Medical University Hospital, Taichung City, 40201, Taiwan. 5. Institute of Medicine, Chung Shan Medical University, Taichung City, 40201, Taiwan. 6. Graduate Institute of Integrated Medicine, China Medical University, No. 110, Sec. 1, Jianguo N. Rd., South District, Taichung City, 40201, Taiwan. 7. Management Office for Health Data, China Medical University Hospital, 3F., No. 373-2, Jianxing Road, Taichung, 40459, Taiwan. 8. College of Medicine, China Medical University, No. 110, Sec. 1, Jianguo N. Rd., South District, Taichung City, 40201, Taiwan. 9. Institute of Population Health Sciences, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County, 35053, Taiwan. 10. Department of Health Services Administration, China Medical University, No. 91, Hsueh-Shih Road, Taichung, 40402, Taiwan. 11. Department of Family Medicine, Min-Sheng General Hospital, 168 ChingKuo Road, Taoyuan, 33044, Taiwan. 12. Faculty of Medicine, National Yang-Ming University School of Medicine, No. 155, Sec. 2, Linong Street, Taipei, 11221, Taiwan. mchou@vghtpe.gov.tw. 13. Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shipai Road, Beitou District, Taipei, 11217, Taiwan. mchou@vghtpe.gov.tw. 14. Faculty of Medicine, National Yang-Ming University School of Medicine, No. 155, Sec. 2, Linong Street, Taipei, 11221, Taiwan. chhwu@vghtpe.gov.tw. 15. Section of Endocrinology and Metabolism, Department of Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shipai Road, Beitou District, Taipei, 11217, Taiwan. chhwu@vghtpe.gov.tw.
Abstract
BACKGROUND: Insulin is highly recommended for diabetes management in persons with liver cirrhosis. However, few studies have evaluated its long-term effects in these persons. We conducted this study to compare the risks of mortality, liver-related complications, and cardiovascular events in persons with type 2 diabetes mellitus (T2DM) and compensated liver cirrhosis. METHODS: From January 1, 2000, to December 31, 2012, we selected 2047 insulin users and 4094 propensity score-matched nonusers from Taiwan's National Health Insurance Research Database. Cox proportional hazard models were used to assess the risks of outcomes. RESULTS: The mean follow-up time was 5.84 years. The death rate during the follow-up period was 5.28 and 4.07 per 100 person-years for insulin users and nonusers, respectively. In insulin users, the hazard ratios and 95% confidence intervals (CIs) of all-cause mortality, hepatocellular carcinoma, decompensated cirrhosis, hepatic failure, major cardiovascular events, and hypoglycemia were 1.31 (1.18-1.45), 1.18 (1.05-1.34), 1.53 (1.35-1.72), 1.26 (1.42-1.86), 1.41 (1.23-1.62), and 3.33 (2.45-4.53), respectively. CONCLUSIONS: This retrospective cohort study indicated that among persons with T2DM and compensated liver cirrhosis, insulin users were associated with higher risks of death, liver-related complications, cardiovascular events, and hypoglycemia compared with insulin nonusers.
BACKGROUND:Insulin is highly recommended for diabetes management in persons with liver cirrhosis. However, few studies have evaluated its long-term effects in these persons. We conducted this study to compare the risks of mortality, liver-related complications, and cardiovascular events in persons with type 2 diabetes mellitus (T2DM) and compensated liver cirrhosis. METHODS: From January 1, 2000, to December 31, 2012, we selected 2047 insulin users and 4094 propensity score-matched nonusers from Taiwan's National Health Insurance Research Database. Cox proportional hazard models were used to assess the risks of outcomes. RESULTS: The mean follow-up time was 5.84 years. The death rate during the follow-up period was 5.28 and 4.07 per 100 person-years for insulin users and nonusers, respectively. In insulin users, the hazard ratios and 95% confidence intervals (CIs) of all-cause mortality, hepatocellular carcinoma, decompensated cirrhosis, hepatic failure, major cardiovascular events, and hypoglycemia were 1.31 (1.18-1.45), 1.18 (1.05-1.34), 1.53 (1.35-1.72), 1.26 (1.42-1.86), 1.41 (1.23-1.62), and 3.33 (2.45-4.53), respectively. CONCLUSIONS: This retrospective cohort study indicated that among persons with T2DM and compensated liver cirrhosis, insulin users were associated with higher risks of death, liver-related complications, cardiovascular events, and hypoglycemia compared with insulin nonusers.
Authors: S Gentile; G Guarino; F Strollo; M Romano; S Genovese; M Masarone; A Ceriello Journal: Diabetes Res Clin Pract Date: 2016-01-09 Impact factor: 5.602
Authors: Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews Journal: Diabetes Care Date: 2012-04-19 Impact factor: 19.112
Authors: Justin F Creeden; Zachary A Kipp; Mei Xu; Robert M Flight; Hunter N B Moseley; Genesee J Martinez; Wang-Hsin Lee; Khaled Alganem; Ali S Imami; Megan R McMullen; Sanjoy Roychowdhury; Atta M Nawabi; Jennifer A Hipp; Samir Softic; Steven A Weinman; Robert McCullumsmith; Laura E Nagy; Terry D Hinds Journal: Hepatology Date: 2022-04-08 Impact factor: 17.298
Authors: Diego García-Compeán; Emanuela Orsi; Ramesh Kumar; Felix Gundling; Tsutomu Nishida; Jesús Zacarías Villarreal-Pérez; Ángel N Del Cueto-Aguilera; José A González-González; Giuseppe Pugliese Journal: World J Gastroenterol Date: 2022-02-28 Impact factor: 5.742
Authors: Olufunto O Badmus; Sarah A Hillhouse; Christopher D Anderson; Terry D Hinds; David E Stec Journal: Clin Sci (Lond) Date: 2022-09-30 Impact factor: 6.876